Jordi will be responsible for spearheading the commercial development of Reb A in the United States. His appointment follows the FDA’s issuance of a no objection letter in December, which gave high-purity Reb A Generally Recognised As Safe (“GRAS”) status, allowing high-purity Reb A to be adopted as a key ingredient in mainstream food and beverage production and across entire product ranges.
